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Abstract
Parkinson’s, Alzheimer’s and Huntington’s diseases are chronic neurodegenerative disorders of a 
progressive nature which lead to a considerable deterioration of the quality of life. Their 
pathomechanisms display some common features, including an imbalance of the tryptophan 
metabolism. Alterations in the concentrations of neuroactive kynurenines can be accompanied by 
devastating excitotoxic injuries and metabolic disturbances. From therapeutic considerations, 
possibilities that come into account include increasing the neuroprotective effect of kynurenic 
acid, or decreasing the levels of neurotoxic 3-hydroxy-L-kynurenine and quinolinic acid. The 
experimental data indicate that neuroprotection can be achieved by both alternatives, suggesting 
opportunities for further drug development in this field.
Keywords: kynurenines, kynurenic acid, kynurenine aminotransferase, 
Parkinson’s disease, Alzheimer’s disease, Huntington’s disease
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Introduction
Despite the different clinical and neuropathological entities, the pathomechanisms
of chronic neurodegenerative disorders reveal a number of common features in 
their devastating processes. A disturbance of the mitochondrial function, 
glutamate excitotoxicity and a change in the tryptophan metabolism all surely 
accompany the development of Parkinson’s disease (PD), Alzheimer’s disease 
(AD) and Huntington’s disease (HD), among others (Fig. 1).
Glutamate excitotoxicity and the kynurenine pathway
The enhanced release of glutamate, the main excitatory amino acid in the brain, 
gives rise to prolonged stimulation of its receptors and, via a complex 
pathomechanism, induces devastation of the postsynaptic neurons. This process of
glutamate-induced excitotoxicity, first described nearly four decades ago (Olney, 
1969), may be linked with a mitochondrial dysfunction, because the energy 
impairment can lead to partial membrane depolarization, resulting in relief of the 
magnesium block of the N-methyl-D-aspartate (NMDA) channel. Thus, even in 
physiological concentrations, glutamate can evoke downstream events such as a 
Ca2+ overload and free radical generation, inducing a self-propagating process 
(Henneberry 1997).
The kynurenine pathway is the main pathway of the tryptophan metabolism (Wolf
1974), which is primarily responsible for NAD+ and NADP+ production (Fig. 2). 
The central compound of the pathway is L-kynurenine (L-KYN), which can be 
metabolized in two distinct routes to kynurenic acid (KYNA) or to 3-hydroxy-L-
kynurenine (3-OH-L-KYN) and quinolinic acid (QUIN; Guidetti et al. 1995). 
These three metabolites are commonly referred to as neuroactive kynurenines 
(reviewed by Vécsei 2005; Sas et al. 2007; Robotka et al. 2008). KYNA is formed
from L-KYN by an irreversible transamination catalyzed by three subtypes of 
kynurenine aminotransferases (KATs; Okuno et al. 1991; Yu et al. 2006) and 
mitochondrial aspartate aminotransferase (mitAAT). KAT-II has been 
demonstrated to be the main KYNA-producing enzyme in the rat and human 
brains, while in the mouse brain mitAAT possesses the highest activity and KAT-
II the lowest (Guidetti et al. 2007). KYNA is a broad-spectrum endogenous 
antagonist of ionotropic excitatory amino acid receptors (Perkins and Stone 1982).
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In micromolar concentrations, it acts as a competitive antagonist at the strychnine-
insensitive glycine-binding site of the NMDA receptor (Kessler et al. 1989) and 
exerts weak antagonistic effects on the α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) and kainate receptors (Birch et al. 1988). It has been 
reported that KYNA in low (nanomolar to micromolar) concentrations can 
facilitate AMPA receptor responses (Prescott et al. 2006), but the concentration 
range is controversial: KYNA in micromolar concentrations was recently claimed 
to have a neuroinhibitory effect, whereas in nanomolar concentrations it behaves 
as a facilitator (Rózsa et al. 2008). It is also important that KYNA non-
competitively blocks the α7-nicotinic acetylcholine receptors (Hilmas et al. 2001),
activation of which at the presynaptic site is involved in the regulation of 
glutamate release (Marchi et al. 2002). Another interesting fact is that the 
neuronal expression of KAT-I seems to have effects on developmental processes, 
such as programmed cell death (Csillik et al. 2002b). QUIN and 3-OH-L-KYN, 
both neurotoxic compounds, are formed by the action of 3-hydroxyanthranilate 
3,4-dioxygenase and kynurenine 3-hydroxylase, respectively (Foster et al. 1986; 
Battie and Verity 1981). QUIN is a weak, but specific competitive agonist of the 
NMDA receptor subgroup containing the NR2A and NR2B subunits (de Carvalho
et al. 1996), with low receptor affinity. Via the direct activation of NMDA 
receptors (Stone and Perkins 1981) or the release and uptake inhibition of 
endogenous glutamate (Connick and Stone 1988; Tavares et al. 2002), it can cause
excitotoxicity. It also induces lipid peroxidation (Rios and Santamaria 1991) and 
the production of reactive oxygen species (Behan et al. 1999). The effects of 3-
OH-L-KYN are mediated by free radicals and not glutamate receptors (Eastman 
and Guilarte 1990; Okuda et al. 1998). Some of its deleterious actions could be 
due to its metabolite, 3-hydroxyanthranilic acid (3-OH-ANA), which readily 
undergoes auto-oxidation with the production of O2.- (Dykens et al. 1987), and it 
has also been shown to be neurotoxic (Jhamandas et al. 1990).
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The role of kynurenine pathway abnormalities in chronic 
neurodegenerative disorders
Parkinson’s disease
PD is a progressive neurodegenerative disorder, clinically characterized by resting
tremor, rigidity, bradykinesia and postural instability. The pathological hallmarks 
are a preferential loss of dopaminergic neurons in the substantia nigra pars 
compacta (SNPC) and the presence of Lewy bodies. Neurons in the substantia 
nigra possess NMDA receptors and receive glutamatergic input from the 
subthalamic nucleus, cerebral cortex, amygdala and pedunculopontine and 
laterodorsal tegmental nuclei (reviewed by Misgeld 2004). In consequence of the 
defect in mitochondrial complex I activity (Reichmann and Riederer 1989; 
Schapira et al. 1989), the dopaminergic neurons become more vulnerable to 
excitotoxicity (reviewed by Beal 1998). This process may be linked with a 
disturbance of the tryptophan metabolism, as suggested by the observation that the
expression of KAT-I in the substantia nigra of mice is decreased after 1-methyl-4-
phenyl-1,2,3,6,-tetrahydropyridine (MPTP; for the inhibition of mitochondrial 
complex I) treatment (Knyihár-Csillik et al. 2004). Further, densitometric analysis
has proved that 6-hydroxydopamine (a free radical generator in catecholaminergic
neurons) treatment considerably diminishes not only tyrosine hydroxylase, but 
also KAT-I immunoreactivity in the remaining SNPC neurons (Knyihár-Csillik et 
al. 2006). In rat cerebral cortical slices, 1-methyl-4-phenylpyridinium ion (MPP+; 
the neuroactive metabolite of MPTP) considerably diminished KAT-II activity, 
with the resulting depletion of KYNA (Luchowski et al. 2002). In accordance 
with these findings, lowered KYNA concentrations have been measured in the 
frontal cortex, putamen and SNPC of patients with PD (Ogawa et al. 1992), and 
thus KYNA is probably unable to inhibit NMDA receptors effectively and to 
prevent excitotoxicity. Conversely, 3-OH-L-KYN concentrations have been found
to be elevated, probably contributing to the oxidative damage seen in PD.
Alzheimer’s disease
AD is likewise a progressive neurodegenerative disorder accompanied by 
dementia and characterized by neuropathological lesions such as neurofibrillary 
tangles and β-amyloid (Aβ) plaques, mainly in the areas responsible for memory 
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formation consisting of glutamatergic circuits. A marked decrease in 
mitochondrial complex IV activity suggests that an energy impairment plays a 
crucial role in the development of AD, too (Kish et al. 1992). Together with other 
enzyme disturbances, it can result in ATP depletion and the increased production 
of free radicals and Aβ. Glutamate excitotoxicity is a further key event in the 
pathogenesis of AD, for a Ca2+ overload can lead to the increased activation of 
kinases with the consequential formation of neurofibrillary tangles due to tau 
hyperphosphorylation (reviewed by Greenamyre and Young 1989). Alterations in 
the kynurenine pathway have also been implicated in the pathological process. 
Sodium azide (inhibitor of mitochondrial complex IV) treatment can alter the 
expression of KAT-I: the glial immunoreactivity has been found to be decreased, 
while the neurons have started to express KAT-I (Knyihár-Csillik et al. 1999). A 
slightly elevated hippocampal KYNA concentration has been found in post-
mortem AD brains (Baran et al. 1999), with no alterations in the activities of 
either KAT-I or KAT-II in this key brain region in AD. However, the same study 
revealed a significantly elevated KYNA concentration with an increased KAT-I 
activity in the caudate nucleus and putamen, and a moderately enhanced KAT-II 
activity only in the putamen. This may be a compensatory mechanism due to the 
pronounced degeneration of the corticostriatal pathway in AD (Francis et al. 
1993), with increased glutamate binding in the striatum (Ułas et al. 1994). The 3-
OH-L-KYN content in the AD brain merely tends to decrease and does not seem 
to have an important role in the pathomechanism. However, Aβ can induce the 
production of QUIN by the microglia and macrophages to a neurotoxic level 
(reviewed by Guillemin and Brew 2002). This was proved by the 
immunohistochemical analysis of post-mortem AD brains, where massive 
increases were found both in indoleamine 2,3-dioxygenase (the enzyme 
responsible for the production of L-KYN) and in QUIN immunoreactivity, mainly
in the perimeter of senile plaques (Guillemin et al. 2005). These data suggest the 
upregulation of the kynurenine pathway in AD, leading mainly to the excessive 
local production of QUIN due to neuroinflammatory processes, and also to an 
elevation in KYNA level, which is nevertheless unable to alleviate the deleterious 
neurotoxic effects of QUIN.
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Huntington’s disease
HD is an autosomal dominantly inherited neurodegenerative disorder, 
characterized clinically by cognitive, psychiatric and motor symptoms and 
pathologically by the development of neuronal intranuclear inclusions in certain 
brain regions. The loss of medium-sized spiny neurons (MSNs) in the striatum is 
most pronounced. A mitochondrial dysfunction is indicated by a decreased 
activity of succinate dehydrogenase in post-mortem HD brains (Stahl and 
Swanson 1974). 3-Nitropropionic acid (inhibitor of succinate dehydrogenase) 
treatment reduces the activity of KAT-I most markedly in the striatum of the rat 
brain, suggesting a link between the metabolic disturbances and an altered 
tryptophan metabolism in HD (Csillik et al. 2002a). Further, when rat cerebral 
cortical slices were used, the activities of KAT-I and KAT-II proved to be 
decreased, with the resulting depletion of KYNA (Luchowski et al. 2002). 
Glutamate excitotoxicity too may play an important role in the development of 
HD (Coyle and Schwarcz 1976; McGeer and McGeer 1976; DiFiglia 1990). 
Selective impairment of the MSNs may be explained by their receiving massive 
glutamatergic inputs from the cortex and the thalamus (Fonnum et al. 1981; Smith
et al. 2004). On the other hand, the NMDA receptors are present in especially 
high amounts on the spines of the MSNs, and the pattern of expression of the 
receptor subunits differs from that of the other striatal neurons (Landwehrmeyer et
al. 1995). An imbalance has been demonstrated between the levels of the 
neuroactive kynurenines in the striatum in different stages of HD (Guidetti et al. 
2004): the level of QUIN is significantly elevated in low-grade HD brains, but 
normal or decreased in higher-grade cases. The elevation in QUIN concentration 
correlates well with the increased activity of its producing enzyme, 3-
hydroxyanthranilate 3,4-dioxygenase in HD brains (Schwarcz et al. 1988). The 
pathogenetic role of QUIN in the development of HD is supported by the fact that 
its intrastriatal injection is highly applicable for the animal modelling of HD 
(Schwarcz and Köhler 1983; Beal et al. 1986; Vécsei and Beal 1991). A KYNA 
level deficiency and decreased activities of KAT-I and KAT-II in the striatum of 
HD patients (Beal et al. 1990; Jauch et al. 1995) have also been proposed to be 
related to the development of the disease. In correlation to the findings detailed 
above, young mice with decreased KYNA and normal 3-OH-L-KYN and QUIN 
concentrations due to the targeted deletion of KAT-II displayed an increased 
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vulnerability to the intrastriatal injection of QUIN as compared with the wild-type
controls (Sapko et al. 2006). The striatal concentration of 3-OH-L-KYN, which 
potentiates the neurotoxic effects of QUIN in the rat striatum (Guidetti and 
Schwarcz 1999), changes in parallel with the QUIN level in HD; Person and 
Reynolds (1992) have reported it to be elevated. The roles of neuroactive 
kynurenines accompanying the development of HD have been investigated by 
means of a yeast genomic screen, too, which revealed that the deletion of the 
KYNA-producing enzyme enhances mutant huntingtin-mediated toxicity, whereas
mainly the deletion of 3-OH-L-KYN, but also that of the QUIN-producing 
enzyme ameliorates it (Giorgini et al. 2005).
Modulation of the kynurenine pathway as a future therapeutic 
strategy
From a therapeutic aspect, the findings detailed above suggest several possibilities
which might be utilized in an effort to prevent or at least to mitigate these 
neurodegenerative processes. As concerns the kynurenines, enhancement of the 
effects of KYNA or reduction of the levels of 3-OH-L-KYN and QUIN may come
into consideration (reviewed by Schwarcz 2004). As the blood-brain penetration 
of KYNA is poor (Fukui et al. 1991), the former aim may be achieved by the 
administration of KYNA analogues (reviewed by Stone 2000) or pro-drugs that 
can cross the blood-brain barrier or by inducing an elevation of the endogenous 
KYNA level. In relation to PD, the co-infusion of exogenous KYNA with either 
QUIN or NMDA into the SNPC led to the preservation of striatal tyrosine 
hydroxylase activity (Miranda et al. 1997). In accordance with these results, 
KYNA, but surprisingly not the more selective glycine/NMDA receptor 
antagonist 7-chlorokynurenic acid (7-Cl-KYNA), afforded partial protection 
against the intrastriatal neurotoxic effect of MPP+ in rats (Merino et al. 1999). 
Accordingly, 5,7-dichlorokynurenic acid too did not reverse the AD-type 
abnormal hyperphosphorylation of tau induced by the phosphatase inhibitor 
okadaic acid in hippocampal organotypic cultures (Li et al. 2004). However, the 
systemic administration of 4-chlorokynurenine (4-Cl-KYN), the blood-brain 
penetrable pro-drug of 7-Cl-KYNA, did prevent quinolinate-induced 
neurotoxicity in the rat hippocampus (Wu et al. 2000). Furthermore, it also 
provided protection in the rat striatum in the quinolinate and malonate (inhibitor 
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of succinate dehydrogenase) models of HD (Guidetti et al. 2000). The seeming 
controversy between these experimental findings can be explained on the one 
hand by the fact that the halogenation of KYNA results in compounds that are 
highly selective for the glycine site of NMDA receptors (Leeson et al. 1991) and 
can mainly prevent NMDA receptor-mediated excitotoxicity, but 
neurodegenerative processes involve a wider spectra of neurotransmitter receptors
and intracellular signalling pathways. On the other hand, 4-Cl-KYN can be 
metabolized to 4-chloro-3-hydroxyanthranilate, a powerful inhibitor of QUIN 
synthesis (Parli et al. 1980), broadening the modes of neuroprotective action. 
However, it is important to mention here that the inhibition of kynurenine 3-
hydroxylase rather selected, as blockade of 3-hydroxyanthranilate 3,4-
dioxygenase activity may result in the accumulation of 3-OH-ANA (Fornstedt-
Wallin et al. 1999), which can exert neurotoxic effects, thereby decreasing the 
potency of neuroprotection. The combination of nicotinylalanine, an agent that 
inhibits both kynurenine 3-hydroxylase and kynureninase activity, with L-KYN 
and probenecid, an inhibitor of organic acid transport, protects the dopaminergic 
cells in the SNPC against NMDA and QUIN-induced excitotoxicity through the 
elevated KYNA level (Miranda et al. 1997), and also alleviates QUIN-mediated 
neurotoxicity in the rat striatum (Harris et al. 1998). Furthermore, 3,4-dimethoxy-
N-[4-(3-nitrophenyl)thiazol-2-yl]benzenesulfonamide (Ro 61-8048), a potent non-
competitive inhibitor of kynurenine 3-hydroxylase, proved to be protective in a 
yeast model of HD (Giorgini et al. 2005). Although these small molecule 
kynurenine 3-hydroxylase inhibitors alone cannot elevate the physiological level 
of KYNA (Moroni et al. 1991), Amori et al. (2009) made the interesting recent 
finding that in excitotoxically lesioned neuron-depleted striata (1S,2S)-2-(3,4-
dichlorobenzoyl)-cyclopropane-1-carboxylic acid (UPF 648) moderately 
enhanced the KYNA synthesis.
Conclusion
The encouraging experimental data emerging from the activities in the field of 
neuroscience, dealing with the connection between chronic neurodegenerative 
disorders and the kynurenine pathway, justify the continuation of research in this 
area, with a view to future drug development. The uses of 4-Cl-KYN and small 
molecule enzyme inhibitors alike have a great promise, and the design of blood-
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brain penetrable KYNA analogues with preserved pharmacological activity also 
would be a successful therapeutic strategy.
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Figure legends
Figure 1 Common pathways in chronic neurodegenerative disorders.
Figure 2 The kynurenine pathway of the tryptophan metabolism.
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